Skip to main content
. 2012 Nov 27;7(11):e44369. doi: 10.1371/journal.pone.0044369

Figure 2. COX-2 inhibitor treatment initiated 3 weeks after beginning AngII infusion effectively reduces AAA progression in ApoE-deficient mice.

Figure 2

(A) AAA incidence was determined at necropsy following 3 (3 Wks AngII) or 8 weeks (Control and Celecoxib) of AngII infusion. (B) The maximal external diameter or (C) AAA classification of the suprarenal aorta following 3 (3 Wks AngII) or 8 weeks (Control and Celecoxib) of AngII infusion. For aortic diameter, results depict mean ± SEM. AAA incidence and diameter: 3 Wks AngII n = 12, Control n = 13, Celecoxib n = 14. P values were determined for incidence data using Fisher's exact test and an unpaired two-tailed t-test for aortic diameter. * indicates P<0.05.